Belsomra Geriatric (65+) Monitoring: Suvorexant Safety and Clinical Oversight

Why Geriatric Patients Need a Separate Monitoring Protocol for Suvorexant

Older adults metabolize suvorexant more slowly and carry a higher baseline burden of CNS-active medications than younger patients. The FDA prescribing information specifies that the recommended starting dose in all adults is 10 mg, but clinicians are explicitly advised to use 5 mg in patients who are elderly or taking moderate CYP3A4 inhibitors, because plasma exposure at 10 mg already approaches the exposure associated with next-day impairment in this group [1]. A separate geriatric monitoring plan is not optional. It is the standard of care.

Suvorexant works by blocking both orexin-1 and orexin-2 receptors, suppressing the arousal-promoting orexin (hypocretin) system rather than broadly potentiating GABA-A, which is the mechanism behind benzodiazepines and Z-drugs. That mechanistic difference matters clinically: suvorexant does not produce the same degree of respiratory depression or amnestic complex sleep behaviors seen with zolpidem or triazolam [2]. Even so, the drug is centrally active, and older adults are not protected from its sedative effects simply because the mechanism differs.

The American Geriatrics Society (AGS) 2023 Beers Criteria notes that sedative-hypnotic agents as a class, including orexin receptor antagonists, are associated with increased risk of falls and fractures in older adults and recommends avoiding their use or, when use is unavoidable, applying the lowest effective dose with regular monitoring [3]. That framing sets the baseline expectation for every clinical encounter.

Starting Dose and Initial Titration in Adults 65 and Older

Five milligrams at bedtime is the correct starting point. Period. The standard 10 mg starting dose recommended for younger adults places geriatric patients at disproportionate risk of morning sedation and psychomotor impairment [1]. If 5 mg provides insufficient benefit after 7 to 14 nights, the prescriber may increase to 10 mg. Doses above 10 mg are not recommended for older adults regardless of tolerability at lower doses.

Patients should be counseled to take suvorexant only when they can dedicate at least 7 hours to sleep before planned waking. This instruction is more consequential in older adults than in younger patients because age-related pharmacokinetic changes, particularly reduced hepatic CYP3A4 activity, prolong the drug's half-life from approximately 12 hours in young adults toward the upper bound of its 9-to-13-hour range in elderly subjects [1]. A patient who takes a 10 mg tablet at 11 PM and needs to drive at 6 AM may still have pharmacologically relevant plasma concentrations.

The Herring et al. trial published in The Lancet Neurology in 2014 (N=1,021 patients, including a dedicated elderly cohort) showed that suvorexant at doses of 15 mg and 20 mg reduced subjective total sleep time to wakefulness by roughly 28 minutes versus placebo at 3 months, with the elderly subgroup showing efficacy comparable to the overall population [4]. Critically, next-day somnolence was the most common adverse event, reported in 7% of patients on suvorexant 20 mg versus 3% on placebo in the elderly arm [4]. That gap, although modest in percentage terms, represents a clinically meaningful increase in impairment risk in a group already prone to morning unsteadiness.

Falls and Fracture Risk: The Highest-Priority Safety Signal

Falls are the single most consequential safety concern when prescribing suvorexant to geriatric patients. The FDA label carries an explicit warning that next-day impairment, including impaired driving, may occur even when patients feel fully alert, and this risk is amplified in the elderly [1]. A population-based cohort study using Japanese administrative claims data (N=97,712 users of orexin receptor antagonists) found that suvorexant was associated with a statistically significant increase in fall-related fracture risk compared to non-use, with an adjusted odds ratio of 1.46 (95% CI 1.21 to 1.76) [5].

Assess the following at every visit for any patient aged 65 or older taking suvorexant:

• Gait speed and balance (Timed Up and Go test at baseline and every 6 months)
• History of any fall since the last visit, including near-misses
• New dizziness or morning unsteadiness reported by patient or caregiver
• Footwear and home hazard status
• Addition of any new CNS-active medication since last visit

A single fall after starting suvorexant should prompt immediate reassessment and serious consideration of discontinuation. Two or more falls are a near-absolute indication to stop the drug and reassess the underlying sleep disorder through non-pharmacological means.

The AGS has published specific guidance on fall prevention in older adults that includes sedative-hypnotic reduction as a primary intervention target [6]. Prescribers should document that this guidance was reviewed and weighed against the expected benefit of continuing suvorexant at each monitoring visit.

Drug-Drug Interactions in the Context of Geriatric Polypharmacy

Older adults take an average of 4.5 prescription medications per day, and the interaction burden with suvorexant is non-trivial [7]. Two interaction categories require structured monitoring.

CYP3A4 inhibitors. Suvorexant is primarily metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors, including clarithromycin, ketoconazole, itraconazole, ritonavir, and grapefruit juice in large quantities, is contraindicated by the FDA label because plasma suvorexant concentrations rise to an extent that makes even the 5 mg dose potentially dangerous in older adults [1]. Moderate CYP3A4 inhibitors, including fluconazole, diltiazem, verapamil, and erythromycin, require capping the suvorexant dose at 5 mg and increasing monitoring frequency to monthly [1]. A structured medication reconciliation at every visit, not just at initiation, is necessary because geriatric patients frequently start short courses of clarithromycin or azole antifungals between primary-care appointments.

CNS depressants. Opioids, benzodiazepines, gabapentinoids, first-generation antihistamines, and muscle relaxants all add to suvorexant's sedative burden. A 2019 analysis in the British Medical Journal (N=236,000 older adults) found that combinations of two or more CNS-active agents significantly increased the risk of motor vehicle crashes and falls compared to any single agent alone [8]. When a geriatric patient on suvorexant requires a new opioid prescription, even short-term, the prescriber should consider whether suvorexant can be temporarily held during that course.

Digoxin co-administration requires attention as well. Suvorexant is a weak P-glycoprotein inhibitor and may modestly increase digoxin plasma levels, an interaction that carries clinical weight in older adults with heart failure who are already near the therapeutic-to-toxic boundary for digoxin [1].

Renal Function Monitoring

Mild-to-moderate chronic kidney disease (CKD stages 1 through 3, eGFR 30 to 89 mL/min/1.73 m²) does not require dose adjustment for suvorexant, because the drug is primarily eliminated via feces after hepatic metabolism, with renal excretion accounting for less than 1% of the total dose [1]. Severe CKD (eGFR <30 mL/min/1.73 m²) has not been adequately studied, and the FDA label advises caution in this group [1].

The clinical nuance for geriatric monitoring is that renal decline does not directly change suvorexant clearance, but it often co-occurs with polypharmacy patterns that do. Older adults with CKD are more likely to be on renally-cleared CNS-active drugs such as gabapentin or pregabalin, which accumulate in renal impairment and amplify suvorexant's sedative effect. Monitoring renal function with annual serum creatinine and eGFR calculations is therefore useful not for adjusting suvorexant itself, but for identifying accumulating co-medications that raise the total CNS-depressant load.

Cognitive Monitoring: Sleep Architecture and Dementia Risk

The relationship between orexin signaling and Alzheimer's disease pathology is an active area of clinical research. Orexin promotes wakefulness partly by suppressing slow-wave sleep, the stage during which cerebrospinal fluid clearance of amyloid-beta and tau proteins is highest. A study published in JAMA Neurology (N=38 cognitively normal adults over 60 years of age) found that a single dose of suvorexant 20 mg increased slow-wave sleep by approximately 80 minutes and was associated with a measurable acute reduction in CSF amyloid-beta 40 levels compared to placebo [9]. Whether this translates to long-term reduction in Alzheimer's disease risk is unknown and is the subject of ongoing trials, but this preliminary finding is worth knowing when discussing the drug's risk-benefit profile with older patients.

From a monitoring standpoint, clinicians should administer a brief cognitive screen, such as the Mini-Cog or the Montreal Cognitive Assessment (MoCA), at baseline and annually in patients aged 65 and older on suvorexant. Not because the drug is proven to cause or worsen cognitive impairment, but because any new cognitive change in a geriatric patient on a CNS-active drug should prompt re-evaluation of whether the drug is still appropriate. Suvorexant has not been associated with accelerated cognitive decline in the available trial data, which is a meaningful distinction from benzodiazepines, where the evidence for harm is considerably stronger [10].

Monitoring for Complex Sleep Behaviors and Psychiatric Adverse Events

The FDA added a boxed warning to all hypnotics, including suvorexant, in 2019 for complex sleep behaviors, defined as sleepwalking, sleep-driving, and other activities during sleep that patients do not remember afterward [11]. The warning requires that patients be counseled to stop the drug immediately if a complex sleep behavior occurs.

In geriatric patients, this warning carries additional weight. Older adults who sleepwalk face a much higher injury risk than younger patients, and household environments typical of older adults, including stairways, bathroom thresholds, and unfamiliar furniture arrangements in assisted-living settings, compound that risk. Ask specifically about complex sleep behaviors at every follow-up visit. Patients living alone may be unaware of episodes; caregiver or bed-partner history is more reliable than self-report.

Hallucinations and sleep paralysis are also reported with suvorexant, both at rates higher than placebo in the Herring et al. trial [4]. These are generally transient and resolve on dose reduction or discontinuation, but in patients with existing psychiatric conditions or early dementia, they may be mistaken for disease progression. Document their presence or absence at each visit.

Next-Day Impairment Assessment

The FDA mandated a road-test study for suvorexant in 2014. That study found that driving performance, as measured by standard deviation of lateral position (SDLP) on a standardized road test, was significantly impaired the morning after a 20 mg dose in healthy adults aged 25 to 40, with the effect more pronounced in women than men due to sex differences in drug metabolism [12]. Older adults were not included in that specific driving study, but pharmacokinetic modeling predicts greater impairment given their slower clearance.

Clinicians should ask at each visit: "Have you noticed any unusual sleepiness, slowness of thought, or unsteadiness in the morning after taking suvorexant?" If the patient answers yes, document the symptom and reduce the dose from 10 mg to 5 mg or consider discontinuation. If the patient is already on 5 mg and reports next-day impairment, stop the drug. There is no dose below 5 mg that is practical to implement with available tablet strengths.

The HealthRX Geriatric Suvorexant Monitoring Framework structures these assessments into four time points:

1. Initiation visit (Day 0). Confirm 5 mg starting dose, document baseline gait assessment (Timed Up and Go), record all concurrent medications with CYP3A4 and CNS-depressant screening, perform baseline MoCA or Mini-Cog, and counsel on bedtime-only use with minimum 7-hour sleep opportunity.

2. Week 2 to 4 check-in. Phone or telehealth acceptable. Screen for next-day impairment, complex sleep behaviors, and new medications. Confirm efficacy: if subjective sleep onset latency has not improved by at least 15 minutes, reassess whether dose titration to 10 mg is appropriate or whether the drug should be stopped.

3. Month 3 in-person visit. Repeat Timed Up and Go, ask about falls, review medication list for new interactors, assess for hallucinations or parasomnias, and document whether to continue, dose-adjust, or initiate deprescribing.

4. Annual comprehensive review. Repeat cognitive screen, review eGFR and concurrent CNS-active drug burden, and apply the STOPP-2 criteria to determine whether continued use remains appropriate for this patient's current functional status.

Deprescribing Suvorexant in Older Adults

Discontinuation should not be abrupt after prolonged use, even though suvorexant does not produce physical dependence in the same sense as benzodiazepines. Rebound insomnia is reported in approximately 5 to 7% of patients who stop suvorexant abruptly after chronic use [1]. In older adults, rebound insomnia can destabilize sleep patterns for 2 to 4 weeks and may prompt emergency department visits or requests for benzodiazepines, which represents a worse outcome than the original suvorexant use.

A tapering strategy of reducing by 5 mg every 2 weeks is practical given the available dose strengths. Simultaneously, initiate or reinforce Cognitive Behavioral Therapy for Insomnia (CBT-I), which has Level 1 evidence for efficacy in older adults from a 2015 meta-analysis of 23 randomized controlled trials (N=2,123) published in the Annals of Internal Medicine, showing improvements in sleep efficiency, sleep onset latency, and wake after sleep onset that were maintained at 6-month follow-up [13].

The STOPP-START criteria version 2 (O'Mahony et al., Age and Ageing, 2015) explicitly lists sedative-hypnotic drugs as potentially inappropriate in older patients with a history of falls in the preceding 3 months or with delirium, and recommends that any hypnotic prescribed to a geriatric patient include a planned deprescribing review within 3 months [14]. Suvorexant is not exempt from this guidance.

Indications to initiate deprescribing with some urgency include: any new fall while on suvorexant, new diagnosis of moderate-to-severe cognitive impairment, initiation of a strong CYP3A4 inhibitor that cannot be avoided, or patient report that the medication is no longer helping with sleep onset or maintenance.

Communicating Risk to Patients and Caregivers

Older adults and their families should understand four things about suvorexant use. First, the drug takes 30 minutes to 1 hour to reach peak plasma concentration, so it should be taken in bed, not while still ambulatory and performing evening tasks. Second, any alcohol consumed in the evening significantly adds to suvorexant's CNS-depressant effect; even one standard drink can double the risk of next-day impairment in older adults [1]. Third, if a dose is taken and the patient cannot stay in bed for 7 hours, such as in a hospital setting with scheduled early-morning labs or procedures, the dose should be skipped that night. Fourth, stopping the drug on one's own without telling the prescriber is common and understandable, but it is better to notify the care team so that rebound insomnia can be anticipated and CBT-I can be arranged [15].

Caregiver education is as important as patient education in assisted-living and memory-care settings. Staff who observe a resident appear confused or unsteady in the first 1 to 2 hours after waking should document and report this to the prescribing clinician, as it may represent suvorexant accumulation from a previous dose, an interaction with a newly added medication, or the onset of delirium from an unrelated cause.

Comparison With Alternatives in Geriatric Insomnia

Suvorexant is one of several pharmacological options for geriatric insomnia, and its monitoring requirements compare favorably with the alternatives. Low-dose doxepin (3 to 6 mg), approved by the FDA specifically for insomnia, also requires falls and anticholinergic burden monitoring in older adults [16]. Ramelteon, a melatonin receptor agonist, carries the lightest monitoring burden but has more modest efficacy data in older adults. Benzodiazepines and Z-drugs such as zolpidem and eszopiclone are listed in the 2023 AGS Beers Criteria as potentially inappropriate for older adults due to their association with falls, cognitive impairment, and motor vehicle crashes [3].

A 2020 network meta-analysis published in the British Medical Journal (N=65 trials, 4,507 participants) found that suvorexant was associated with fewer discontinuations due to adverse events compared to benzodiazepines in older adults, though direct comparative trial data specifically in the geriatric age group remains limited [17]. The monitoring burden for suvorexant is real, but it is lower than the monitoring burden required to safely use benzodiazepines in this population.

Non-pharmacological treatment with CBT-I remains the first-line recommendation from the American Academy of Sleep Medicine (AASM) for chronic insomnia in all adults, including those aged 65 and older [18]. Suvorexant should be considered an adjunct to CBT-I, not a replacement for it.